About Regulus Therapeutics Inc. - Common Stock (RGLS)
Regulus Therapeutics is a biotechnology company focused on the development of innovative medicines to treat various diseases by targeting microRNAs, which are small non-coding RNA molecules that play crucial roles in regulating gene expression. The company is dedicated to advancing its proprietary platform to discover and develop novel therapies, particularly for conditions related to kidney disorders, liver diseases, and neurological disorders. Through its cutting-edge research and development efforts, Regulus aims to leverage the potential of microRNA modulation to create effective treatments that can significantly improve patient outcomes. Read More
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Lately, several enterprises have surfaced in the media spotlight for various reasons, potentially catching the eye of investors. This article offers an in-depth examination of five companies that could be worthwhile to monitor.
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also rose, gaining, 1.10% to 5,174.28.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Tuesday. The Dow traded up 0.48% to 38,955.84 while the NASDAQ rose 1.12% to 16,198.58. The S&P 500 also rose, gaining, 0.82% to 5,159.75.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.27% to 38,873.55 while the NASDAQ rose 0.69% to 16,129.18. The S&P 500 also rose, gaining, 0.52% to 5,144.57.
Regulus Therapeutics reports findings for RGLS8429 in ADPKD study—mechanistic dose response, encouraging biomarkers, and an oversubscribed $100M equity placement at $1.60 per share.
Regulus Therapeutics Inc. (NASDAQ: RGLS) is one today’s most active stocks by volume. So far today, approximately 76.96M shares of Regulus Therapeutics Inc. have been exchanged, as compared to an average 30-day volume of 54,867 shares.
